The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 billion in a new funding round
Medical artificial intelligence search platform OpenEvidence achieved a valuation of $15 billion following a $250 million funding round. The clinical intelligence tool is now utilized by nearly two-thirds of United States physicians. As the startup scales to support widespread clinical adoption, its advertising model has begun sparking debate across the healthcare sector. The recent capital injection stands as South Florida's largest third-quarter funding round of 2026, driven by investors Andreessen Horowitz and Byers Capital.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ OpenEvidence is valued at $15 billion.
- ✓ The AI tool reaches nearly two-thirds of United States physicians.
- ✓ The valuation follows a $250 million funding round.
What changed
Public debate has emerged regarding the advertising model utilized by the $15 billion clinical search platform.
Live updates
-
OpenEvidence Reaches $15 Billion Valuation As Doctors Adopt AI Search
Medical artificial intelligence search platform OpenEvidence achieved a valuation of $15 billion following a $250 million funding round. The clinical intelligence tool is now utilized by nearly two-thirds of United States physicians. As the startup scales to support widespread clinical adoption, its advertising model has begun sparking debate across the healthcare sector. The recent capital injection stands as South Florida's largest third-quarter funding round of 2026, driven by investors Andreessen Horowitz and Byers Capital.
Why it matters
Founder and CEO Daniel Nadler operates the enterprise with strategies resembling a hedge fund rather than a conventional healthcare artificial intelligence provider. The clinical tool grounds its search engine answers in peer-reviewed research from major publications including NEJM, JAMA, Nature, NCCN, and Cochrane. The rapid market penetration highlights a significant shift in how medical professionals access clinical research.
What is confirmed
- OpenEvidence is valued at $15 billion.
- The AI tool reaches nearly two-thirds of United States physicians.
- The valuation follows a $250 million funding round.
Still unconfirmed
- The platform's advertising model is actively sparking debate.
What to watch next
- Further details on how the advertising model functions within the clinical search platform
- Additional financial disclosures from OpenEvidence regarding its revenue streams
confidence 100%Sources used for this update (3)
- newsroom.wyde.org — OpenEvidence at $15 billion: its ad model sparks debate
- cryptobriefing.com — OpenEvidence hits $15 billion valuation as AI reshapes how ...
- emergent.sh — OpenEvidence AI: The $15B Startup Doctors Already Use
-
OpenEvidence Faces Scrutiny After Reaching $15 Billion Valuation
Medical search platform OpenEvidence secured a $15 billion valuation in late September 2026 following a $250 million Series D funding round led by Andreessen Horowitz and Byers Capital. Founder and CEO Daniel Nadler confirmed the raise, which stands as South Florida's largest third-quarter funding round of 2026. The clinical intelligence tool grounds its search engine answers in peer-reviewed research from publications such as NEJM, JAMA, Nature, NCCN, and Cochrane. Observers report that Nadler operates the enterprise more akin to a hedge fund than a standard healthcare artificial intelligence provider.
Why it matters
The massive valuation jump highlights aggressive investor spending in the healthcare artificial intelligence sector. Industry analysts caution that funding totals and lofty valuations must not be confused with actual clinical outcomes. OpenEvidence continues to deploy its artificial intelligence search technology on a global scale as America's official medical knowledge platform.
What is confirmed
- OpenEvidence reached a $15 billion valuation after a $250 million Series D funding round led by Andreessen Horowitz and Byers Capital.
- Founder and CEO Daniel Nadler confirmed the raise.
- The clinical intelligence tool provides answers grounded in peer-reviewed research from publications including NEJM, JAMA, Nature, NCCN, and Cochrane.
Still unconfirmed
- People familiar with the company describe how CEO Daniel Nadler runs the company more like a hedge fund than a healthcare AI business.
What to watch next
- Translation of high valuations into realized clinical benefits
- Further deployment of the global artificial intelligence search engine
confidence 90%Sources used for this update (2)
- www.fixhealth.ai — Inside OpenEvidence: The Art of Selling a $500M Company for $15B
- www.iatrox.com — Why Investors Are Putting Billions into Healthcare AI: What ...
-
OpenEvidence Maintains Medical AI Leadership Amid New Funding
Medical search platform OpenEvidence holds its position as America's official medical knowledge platform following a massive valuation jump to $15 billion in late September 2026. The clinical intelligence tool, which reached this milestone after a $250 million Series D funding round led by Andreessen Horowitz and Byers Capital, delivers answers grounded in peer-reviewed research from publications including NEJM, JAMA, Nature, NCCN, and Cochrane. Founder and CEO Daniel Nadler confirmed the raise, marking South Florida's largest funding round of the third quarter of 2026 as the startup deploys its artificial intelligence search engine globally.
Why it matters
The platform provides its core service for free to verified U.S. clinicians while accumulating roughly $1 billion across six outside funding rounds. As clinical artificial intelligence becomes more competitive, market observers are examining the sustainability of these valuations relative to annualized revenue and secondary market trading activity. Concurrently, other academic institutions are adopting broader artificial intelligence tools, evidenced by the University of Maine System launching system-wide ChatGPT Edu access through a two-year contract.
What is confirmed
- OpenEvidence reached a $15 billion valuation following a $250 million Series D funding round in late September 2026.
- Founder and CEO Daniel Nadler confirmed that Andreessen Horowitz and Byers Capital led the investment.
- OpenEvidence provides answers grounded in peer-reviewed research from sources including NEJM, JAMA, Nature, NCCN, and Cochrane.
- The startup has raised approximately $1 billion across six outside rounds.
What to watch next
- Secondary market trading activity affecting OpenEvidence valuation
- Audited annual revenue figures to substantiate the reported valuation
- Competitive developments in clinical artificial intelligence platforms
confidence 100%Sources used for this update (5)
- mainecampus.com — University of Maine implements ChatGPT Edu, source of future funding remains unclear
- stockanalysis.com — OpenEvidence Valuation - Current & Historical - Stock Analysis
- www.openevidence.com — Announcements - OpenEvidence
- www.iatrox.com — Can OpenEvidence Defend a $15 Billion Valuation as Clinical ...
- www.openevidence.com — News | OpenEvidence
-
OpenEvidence Hits $15 Billion Valuation After $250 Million Series D
Medical search platform OpenEvidence reached a $15 billion valuation following a $250 million Series D funding round in late September 2026. Andreessen Horowitz and Byers Capital led the investment, confirmed by founder and CEO Daniel Nadler. The clinical intelligence tool provides answers to medical questions using published research, offering its core service for free to verified U.S. clinicians. This massive raise stands as South Florida's largest funding round of the third quarter of 2026. The startup has raised approximately $1 billion across six outside rounds as it deploys its artificial intelligence search engine globally.
Why it matters
The rapid funding rounds highlight intense investor interest in artificial intelligence tools built specifically for clinical environments. OpenEvidence operates on a business model funded by advertisers while keeping its core product free for doctors. Reliability remains critical for medical AI adoption, underscored by recent independent studies examining clinical intelligence platforms.
What is confirmed
- OpenEvidence secured $250 million in Series D funding, pushing its post-money valuation to $15 billion.
- Andreessen Horowitz and Byers Capital led the funding round, which founder and CEO Daniel Nadler confirmed.
- The company gives clinicians a tool for answering medical questions using published research.
- The core service is free for verified U.S. clinicians.
- OpenEvidence has raised about $1 billion across six outside rounds.
- The $250 million raise in late September was South Florida's largest round of the third quarter.
What to watch next
- Expansion of the clinical intelligence tool across additional global markets and hospital systems
- Further developments in advertising-backed revenue monetization for the free medical search platform
confidence 100%Sources used for this update (9)
- www.businessinsider.com — Big Tech
- pricepertoken.com — AI Funding Tracker — Fundraises, Acquisitions & Deals
- refreshmiami.com — Up, up, up: South Florida on way to another strong VC year, PitchBook’s Q3 report shows
- nextmd.ai — OpenEvidence Is Now Valued at 15 Billion Dollars | NextMD
- www.revenuememo.com — OpenEvidence funding: Every round, investor, and valuation (2026)
- www.distillintelligence.com — Latest OpenEvidence News & Announcements | Distill
- www.forbes.com — Daniel Nadler - Forbes
- www.digitaljournal.com — Fresh NPJ Health Systems study confirms the reliability of ...
- www.businessinsider.com — OpenAI Enlists Doctors to Enhance ChatGPT's Health Advice ...
-
OpenEvidence Hits $15B Valuation With New Funding
Medical search platform OpenEvidence secured $250 million in Series D funding, pushing its post-money valuation to $15 billion. The clinical intelligence tool achieves this valuation on approximately $300 million of run-rate revenue. Known as a ChatGPT-style tool for physicians, the startup is leveraging its financial backing to expand operations. The fresh capital follows a series of rapid fundraising efforts by the company over the past year, drawing massive investments from venture capital heavyweights and hospital systems alike to deploy its artificial intelligence search engine across 100 countries.
Why it matters
The recent capital injection follows a $12 billion valuation in January, demonstrating rapid growth for the clinical intelligence tool. Andreessen Horowitz and hospital systems participated in the round, placing the startup among top technology businesses. The platform now operates in half of U.S. physicians' hands.
What is confirmed
- OpenEvidence secured $250 million in Series D funding.
- The funding round pushed the company's valuation to $15 billion.
- The company was previously valued at $12 billion in January.
- The latest investment came from Andreessen Horowitz and hospital systems.
What to watch next
- Expansion of the artificial intelligence search engine across additional countries
- Further deployment of the clinical tool within hospital systems
confidence 100%Sources used for this update (3)
- stockanalysis.com — OpenEvidence Stock Price, Valuation & News
- distilinfo.com — OpenEvidence Raises $250M at $15B Valuation - distilinfo.com
- ifitnessmag.com — The ‘ChatGPT for Doctors’ Is Now Worth $15 Billion ...
-
OpenEvidence Hits $15 Billion Valuation With New Funding
Medical search platform OpenEvidence secured $250 million in Series D funding, pushing its post-money valuation to $15 billion. The clinical intelligence tool achieves this valuation on approximately $300 million of run-rate revenue. Known as a ChatGPT-style tool for physicians, the startup is leveraging its financial backing to expand operations. The fresh capital follows a series of rapid fundraising efforts by the company over the past year, drawing massive investments from venture capital heavyweights and hospital systems alike to deploy its artificial intelligence search engine across 100 countries.
Why it matters
The massive valuation reflects soaring investor demand for specialized medical artificial intelligence applications that serve clinicians. OpenEvidence has accumulated nearly $800 million over the past year from prominent backers including Nvidia, Thrive Capital, Kleiner Perkins, and Sequoia Capital, alongside the new Series D round led by Andreessen Horowitz. This funding surge highlights the financial premium placed on clinician-facing artificial intelligence tools.
What is confirmed
- OpenEvidence raised $250 million in Series D funding at a $15 billion post-money valuation.
- OpenEvidence operates an AI search platform for physicians.
Still unconfirmed
- OpenEvidence plans to move its focus toward developing its own cancer drugs.
- The company operates on roughly $300 million of run-rate revenue.
What to watch next
- Execution of the reported pivot into developing proprietary cancer drugs
- Future financial disclosures regarding the company's run-rate revenue and drug discovery pipeline
confidence 90%Sources used for this update (3)
- www.winzheng.com — From Doctor Search to Pharmaceutical Company: OpenEvidence ...
- www.metirai.com — OpenEvidence at $15B: Why Medical AI Commands a Premium
- en.wowtale.net — ‘ChatGPT for Doctors’ OpenEvidence Raises $250M, Quietly ...
-
OpenEvidence Valued at $15 Billion in Funding Round
Medical search platform OpenEvidence secured a $250 million investment, pushing its valuation to $15 billion. The clinical intelligence tool, led by CEO Dr. Daniel Nadler, completed back-to-back funding efforts involving hospital systems and Andreessen Horowitz. OpenEvidence deploys its artificial intelligence search engine across 100 countries to assist healthcare providers. The startup has accumulated nearly $800 million over the past year from backers including Nvidia, Thrive Capital, Kleiner Perkins, and Sequoia Capital, reflecting surging demand for specialized medical artificial intelligence applications.
Why it matters
The massive valuation jump follows an earlier financing round in January that valued OpenEvidence at $12 billion. Specialized clinical intelligence startups are capturing immense capital amid a global race to deploy artificial intelligence within the healthcare sector. The rapid financial backing underscores intense investor appetite for tools tailored specifically to medical professionals.
What is confirmed
- Medical search platform OpenEvidence was valued at $15 billion in a new funding round.
- The company raised $250 million in investment from hospital systems and Andreessen Horowitz.
- OpenEvidence was previously valued at $12 billion in a January funding round.
- The startup has raised nearly $800 million over the past year from investors including Nvidia, Thrive Capital, Kleiner Perkins, and Sequoia Capital.
- OpenEvidence deploys its artificial intelligence search engine for doctors in 100 countries.
Still unconfirmed
- OpenEvidence could be open to selling itself due to potential future computing scarcity if rising anti-AI sentiment curbs data center expansion.
- The company may prefer to remain independent rather than pursue a sale.
What to watch next
- Any formal announcement regarding potential mergers or acquisitions involving OpenEvidence.
- Further expansion of the artificial intelligence search engine into additional international markets.
confidence 95%Sources used for this update (7)
- www.theinformation.com — Valuations for Most Robotics Startups Will Fall By 2030, Says Vinod Khosla
- www.businessinsider.com — The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 ...
- b17news.com — The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 ...
- themoneytimes.media — The ‘ChatGPT for doctors,’ OpenEvidence, was valued at $15 ...
- www.livemint.com — What is OpenEvidence, the ‘ChatGPT for doctors’ valued at $15 ...
- article.wn.com — The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 ...
- el7.ai — OpenEvidence Valued at $15 Billion Following $250… | EL7.AI
-
OpenEvidence Valued at $15 Billion in Funding Round
Medical search and clinical intelligence platform OpenEvidence achieved a $15 billion valuation following a new alternative financing round. The company, often described as a ChatGPT for doctors, secured $250 million in the recent transaction. Andreessen Horowitz and Byers Capital led the financing effort for the medical tech platform. The fresh capital influx highlights the rapid commercial growth and investor appetite for artificial intelligence tools tailored specifically to clinical professionals and healthcare providers.
Why it matters
The massive funding round underscores the rising demand for specialized medical artificial intelligence systems designed to assist physicians in clinical workflows. OpenEvidence operates as a tool for medical professionals to find evidence-based clinical information quickly. The participation of prominent venture capital firms like Andreessen Horowitz and Byers Capital reflects strong backing for medical technology infrastructure.
What is confirmed
- OpenEvidence secured a valuation of $15 billion in a new alternative financing round.
- The company reportedly raised $250 million in the financing round.
- Andreessen Horowitz and Byers Capital led the financing round.
What to watch next
- Further details regarding the deployment of the $250 million in capital
- Potential expansion of OpenEvidence clinical AI products and enterprise partnerships
confidence 100%Sources used for this update (5)
- businessinsider.com — The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 billion in a new funding round
- Axios — OpenEvidence reportedly raises $250M at $15B valuation
- healthcare.digital — OpenEvidence secures $250 Million alternative financing round led by Andreessen Horowitz and Byers Capital at $15 Billion valuation
- Digital Health Wire — OpenEvidence’s Quiet Raise and Loud Pivot
- TradingView — OpenEvidence Was Valued At $15 Billion In A New Funding Round - Business Insider
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community